| Document |
Document Title |
|
WO2007147222A9 |
The present invention provides for novel organic salts, more specifically ionic liquids and for methods for the preparation of such novel ionic liquids. The invention also provides for the use of the ionic liquids in chemistry applicatio...
|
|
WO/2008/015517A2 |
The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glau...
|
|
WO/2008/016139A1 |
An oleamide can emit fluorescence without largely deteriorating its biological activity by introducing a fluorescent group into the oleamide via a carbon chain, as shown in the formula (I). The fluorescent group (R) may be a dansyl group...
|
|
WO/2008/014313A2 |
Embodiments in accordance with the present invention are directed to providing processes for forming fluorinated-alkyl and particularly perfluorinated-alkyl sulfonamide substituted norbornene-type monomers.
|
|
WO/2008/009613A1 |
The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula (I) wherein R1, R2, R3, R4, X1 and X2 are as herein...
|
|
WO/2008/007780A1 |
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...
|
|
WO/2008/008431A2 |
Compounds are provided that act as potent antagonists of the CC R2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide...
|
|
WO/2008/008374A2 |
Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally ...
|
|
WO/2008/005851A2 |
Perfluoro lower alkanesulfonamide-derived silanes which in an organic solvent are useful in treating siliceous substrates are described. The compositions may optionally contain an additional non-fluorinated compound in a mixture of conde...
|
|
WO/2008/004673A1 |
Cycloalkene derivatives represented by the general formula (I); medicines containing the derivatives; and a process for the production of the same: (I) [wherein each symbol is as defined in the description]. The cycloalkene derivatives a...
|
|
WO/2008/000969A1 |
The invention relates to compounds of formula (I) wherein R1 is an R4 or NHR4 grouping wherein R4 has the designation defined in the description; R2 is a straight or branched substituted alkyl grouping (C1-C6); and R3 is a hydrogen or ha...
|
|
WO/2007/147762A1 |
Compounds of the formula I or pharmaceutically acceptable salts thereof, wherein Ar, X, m, R1, R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I for t...
|
|
WO/2007/143735A2 |
Certain lipophilic polycationic sulfonamides are provided and are useful for treating various diseases or conditions and particularly sepsis.
|
|
WO/2007/143014A2 |
The present invention relates to novel methods for the preparation of glutamic acid derivatives of formula (I) and intermediates thereof, and such compounds prepared by the novel methods.
|
|
WO/2007/141423A1 |
The invention concerns phenoxy-isobutyric acid derivatives of general formula (I) wherein: R1 and R2 are H, an alkyl group, or a -OR group where R is an alkyl, or R1 and R2 together form a hydrocarbon ring of 3 to 6 carbon atoms; R3 is H...
|
|
WO/2007/138069A1 |
The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits co...
|
|
WO/2007/134971A1 |
The invention relates to benzoyl-substituted alanines of formula (I), in which the variables R1 to R13 are defined as cited in the description, and to their agriculturally useful salts. The invention also relates to methods and intermedi...
|
|
WO/2007/135080A2 |
The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotax...
|
|
WO/2007/131996A1 |
The invention provides compounds of Formula (I) and Formula (II) or a pharmaceutically-acceptable salt, solvate, or hydrate thereof. Compounds of this invention, or pharmaceutical compositions thereof, are useful for treating diabetes, e...
|
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
|
WO/2007/125196A1 |
This invention relates to compounds with the formula (I) given below or one of their pharmaceutically acceptable salts, as a medicine; Formula (I) of pharmaceutical compositions comprising one or more compounds with Formula (I) as active...
|
|
WO/2007/126262A1 |
Disclosed is a novel anion receptor and electrolytes containing the same. A novel anion receptor is an aromatic hydrocarbon compound having an amine substituted with electron withdrawing groups. When the anion receptor is added to the el...
|
|
WO/2007/120647A2 |
The present invention relates to compounds, particularly those of formula (I'), where R, R1, R2, R3, R4, x and z are as defined in the claims, useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceuti...
|
|
WO/2007/118964A1 |
The invention concerns polysubstituted N-(phenethyl)benzamide derivatives, pharmaceutical compositions containing same, as well as their therapeutic uses, in particular in the field of human and animal health. The invention also concerns...
|
|
WO/2007/119110A2 |
The invention relates, in general, to the preparation of (R)(-)tamsulosin free base by reaction of (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide or an addition salt thereof with 1 -(2-bromoethoxy)-2-ethoxybenzene in a polar aprotic s...
|
|
WO/2007/118817A1 |
The present invention refers to compounds of the formula (I) wherein R1, R2, R3 and R4 are defined as given in claim 1, as well as hair dye compositions containing them.
|
|
WO/2007/118852A1 |
The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gas...
|
|
WO/2007/120012A1 |
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The...
|
|
WO/2007/116314A1 |
N-Phenyl-1,1,1 -trifluoromethanesulfonamide compounds of formula 1 a, formula 1 b or formula 1c useful for controlling endo- and/or ectoparasites in the environment are provided, together with methods of making the same and methods of us...
|
|
WO/2007/116374A1 |
The invention relates to sulfonamide compounds of formula (I), where A, B, R3 and R4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types o...
|
|
WO/2007/117981A2 |
The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, ...
|
|
WO/2007/114532A1 |
Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of : reacting aminoacetophenon...
|
|
WO/2007/110876A2 |
Novel sulfonanilide derivatives, preferably derivatives of N-(4-Nitro-2-phenoxy-phenyl)methane-sulfonamide, and their pharmaceutically acceptable salts, esters, amides, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric f...
|
|
WO/2007/107828A2 |
The invention relates to compounds of Formula (1 ) and to intermediates in the preparation of, compositions containing and uses of such derivatives. The compounds according to the present invention are β2 adrenergic receptor agonists an...
|
|
WO/2007/109175A1 |
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive t...
|
|
WO/2007/104144A1 |
There are provided compounds represented by formula (I): in which R1 is F, CI, -N(R5)2 or -CN and Q+ is selected among various organic cations that include an heterocyle. These compounds are useful as electrolytes, ionic liquids or molte...
|
|
WO/2007/098030A1 |
Processes for the preparation of trifluoroalkyl substituted N-(2-hydroxyalkyl) heteroarene- and benzenesulphonamide derivatives of formula (I) or formula (II) (wherein the variables are as defined in the claims) are provided which compri...
|
|
WO/2007/091817A1 |
Disclosed is a novel anion receptor and electrolytes containing the same. A novel anion receptor is a linear hydrocarbon compound having an amine substituted with electron withdrawing groups as (a) terminal group(s). When the anion recep...
|
|
WO/2007/091046A1 |
The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture...
|
|
WO/2007/088276A2 |
The invention concerns sulfonamide derivatives of general formula (I), wherein: Ar1 represents an aryl optionally substituted by one or several groups, an optionally substituted heterocyclyl group; T represents a -(CH2)n or a group (A); ...
|
|
WO/2007/087949A2 |
The invention relates to oxonium salts with [(Ro)3O]+ cations and sulfonium salts with [(Ro)3S]+ cations, wherein Ro represents straight-chain or branched alkyl groups with 1-8 C atoms or unsubstituted phenyl or phenyl that is substitute...
|
|
WO/2007/089069A1 |
The present invention relates to phenyl imidazol sulfonamide derivatives expressed by the above formula I and a method for producing the same, and a whitening cosmetic composition comprising the same. More particularly, the phenyl imidaz...
|
|
WO/2007/085718A1 |
The present invention relates to sulphonamide derivatives corresponding to the general formula (I), in which Ar1 represents an aryl optionally substituted with one or more groups, or an optionally substituted heterocyclyl group; T repres...
|
|
WO/2007/079930A1 |
The present invention relates to substituted cyclohexylmethyl derivatives, to processes for preparing them, to pharmaceuticals comprising these compounds, and to the use of substituted cyclohexylmethyl derivatives for producing pharmaceu...
|
|
WO2006074957A9 |
The invention relates to compounds of general formula (I), wherein the definition of the substituents R1 - R5, A and X are cited in the description, and to the physiologically compatible salts thereof. The invention also relates to a met...
|
|
WO/2007/074553A1 |
According to the invention, a catalyst for a strecker reaction comprising a quaternary ammonium salt and a method for stereoselectively producing an α-aminonitrile derivative using the same are provided. By using the α-aminonitrile der...
|
|
WO/2007/076306A1 |
Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders. wherein: A and R1 to R8 are defined in the specification.
|
|
WO/2007/073168A1 |
The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds around the lead compound (3,4-dichloro-phenyl)-carbamic acid 2-isobutoxycarbonylam...
|
|
WO/2007/071443A1 |
Compounds of formula (I), in which R1 and R2 are independently a substituted phenyl group, where the substituents are as defined in the claims and with the proviso that at least one of the substituents is a cyano, carboxy or (C1-4)alkoxy...
|
|
WO/2007/071638A1 |
The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1 C-4C)alkyl; R2 is hydrogen, halogen or o...
|
